Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

The Bay Zoltan Foundation for Applied Research

Faculty of Medicine of Semmelweis University

Laszlo Rosivall

Yechezkel Barenholz

Janos Szebeni

Katalin Schweitzer

Jozsef Furesz

Miklos Toth

Ferenc Ender

The present invention provides methods for desensitization for prevention or diminishing hypersensitivity reactions including C activation-related pseudoallergy (CARPA) and other reactions to particulate medicines. The desensitization is performed via pretreatment using a drug-free vehicle or carrier to eliminate or diminish the clinical symptoms of hypersensitivity.

Particulate drug carriers as desensitizing agents

The invention relates to a method of using 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione (generic name:pentoxifylline) and/or 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4 -dihydroisoquinolinium theophylline-7-acetate (Depogen) or monohydrate thereof to improve mammalian tissue antioxidant status. This status plays an important role in complications, occurring as a consequence of pathologically developed or artificially established anastomoses, particularly anastomosis of oesophagus and colon since these organs possess a very weak antioxidant protective system.

Method for improving tissue antioxidant status

Growing community of inventors

Budapest, Hungary

Laszlo Rosivall